Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Compensation for Named Executive Officers
On January 7, 2020, the Compensation Committee ("Committee") and the Board of
Directors ("Board") of Opiant Pharmaceuticals, Inc. ("Company"), and in
consultation with the Company's independent compensation consultant, Radford,
approved the following annual base salary increases for the following named
executive officers of the Company, effective January 1, 2020:
Name Title 2020 Base Salary
Dr. Roger Crystal Chief Executive Officer $610,139
Dr. Phil Skolnick Chief Scientific Officer $435,814
David O'Toole Chief Financial Officer $391,608
Option Grants
On January 7, 2020, the Committee and the Board also approved a grant of stock
options to each of Dr. Crystal, Dr. Skolnick and Mr. O'Toole, in the amounts of
27,250 shares, 8,250 shares and 8,250 shares, respectively. Such stock option
grants (i) are exercisable for the purchase of common stock of the Company at
$13.60 per share, (ii) have an exercise period of ten years from the date of
grant, (iii) vest in forty-eight equal monthly amounts starting on the first
monthly anniversary of January 7, 2020, and (iv) were granted under the
Company's 2017 Long-Term Incentive Plan ("2017 LTIP"), which was filed as
Exhibit 10.52 to the Company's Annual Report on Form 10-K filed on October 13,
2017.
On January 7, 2020, the Committee and the Board also approved a grant of
restricted stock units ("RSU") to each of Dr. Crystal, Dr. Skolnick and Mr.
O'Toole, in the amounts of 13,650 shares, 4,150 shares and 4,150, respectively.
Such RSU grants (i) are exercisable in to common stock of the Company, (ii) vest
in four equal annual amounts starting on the first anniversary of January 7,
2020, and (iii) were granted under the Company's 2017 LTIP.
1
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
OPIANT PHARMACEUTICALS, INC. 
